RefDoc
Haut

Faire une nouvelle recherche
Make a new search
Lancer la recherche


Titre du document / Document title

Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors : The hordaland health study

Auteur(s) / Author(s)

RAEDER Maria B. (1 2) ; BJELLAND Ingvar (3) ; VOLLSET Stein Emil (4) ; STEEN Vidar M. (1 2) ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

(1) Dr Einar Martens' Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Helse Bergen HF, Haukeland University Hospital, NORVEGE
(2) Department of Clinical Medicine and Bergen Mental Health Research Center, University of Bergen, NORVEGE
(3) Department of Child and Adolescent Mental Health Services, Haukeland University Hospital, NORVEGE
(4) Department of Public Health and Primary Health Care, Section for Epidemiology and Medical Statistics, University of Bergen, Bergen, NORVEGE

Résumé / Abstract

Objective: This study aimed to examine whether subjects taking selective serotonin reuptake inhibitors (SSRIs) are more likely to have elements of the metabolic syndrome compared with those taking no psychotropic drugs. For comparison, we also studied subjects taking antipsychotic drugs. Method: We used data from The Hordaland Health Study '97-'99, a general community cross-sectional health survey including 25,315 subjects aged 40 to 49 and 70 to 74 years. For the groups studied, we estimated prevalence and odds ratios (ORs) for obesity, hypercholesterolemia, low high-density lipoprotein cholesterol, hypertriglyceridemia, and diabetes. Results: We observed an association between use of SSRIs as a group (N = 461) and abdominal obesity (OR = 1.40, 95% CI = 1.08 to 1.81) and hypercholesterolemia (OR = 1.36, 95% CI = 1.07 to 1.73) after adjusting for multiple possible confounders. There was also a trend toward an association between SSRI use and diabetes. In a subgroup analysis of subjects taking SSRIs, the use of paroxetine (N = 187) was markedly associated with both general and abdominal obesity but not with hypercholesterolemia. In contrast, the use of citalopram (N = 142) was not associated with any of the metabolic outcome variables, while the use of any other SSRI (sertraline, fluoxetine, or fluvoxamine) (N = 131) as a mixed subgroup was associated with both abdominal obesity and hypercholesterolemia. We also replicated the previously reported associations between use of antipsychotics and obesity and metabolic disturbances. Conclusion: We have shown that use of at least some SSRIs is associated with clinical and biochemical elements of the metabolic syndrome. Our data indicate differences in the metabolic side effect profile among various SSRI drugs, although treatment bias might have influenced these results. We suggest that patients taking SSRIs be carefully monitored for obesity and dyslipidemia.

Revue / Journal Title

The Journal of clinical psychiatry    ISSN  0160-6689 

Source / Source

2006, vol. 67, no12, pp. 1974-1982 [9 page(s) (article)] (38 ref.)

Langue / Language

Anglais

Editeur / Publisher

Physicians Postgraduate Press, Memphis, TN, ETATS-UNIS  (1978) (Revue)

Mots-clés anglais / English Keywords

Endocrinopathy

;

Metabolic diseases

;

Nutrition disorder

;

Lipids

;

Nutritional status

;

Health

;

Selective serotonin reuptake inhibitor

;

Diabetes mellitus

;

Dyslipemia

;

Obesity

;

Mots-clés français / French Keywords

Endocrinopathie

;

Métabolisme pathologie

;

Trouble nutrition

;

Lipide

;

Etat nutritionnel

;

Santé

;

Inhibiteur sélectif recapture sérotonine

;

Diabète

;

Dyslipémie

;

Obésité

;

Mots-clés espagnols / Spanish Keywords

Endocrinopatía

;

Metabolismo patología

;

Trastorno nutricíon

;

Lípido

;

Estado nutricional

;

Salud

;

Inhibidor selectivo recaptura serotonin

;

Diabetes

;

Dislipemia

;

Obesidad

;

Localisation / Location

INIST-CNRS, Cote INIST : 9069, 35400015895114.0180

Nº notice refdoc (ud4) : 18367468



Faire une nouvelle recherche
Make a new search
Lancer la recherche
Bas